Lars Sternås

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 794 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

Maurizio Bendandi, Christopher D. Gocke, Carol B. Kobrin et al. · Nature Medicine · 1999 · 591 citations

Vaccination, Lymphoid Neoplasia, Tumor Immunology +12

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors

A. Craig Lockhart, Mace L. Rothenberg, Jakob Dupont et al. · Journal of Clinical Oncology · 2009 · 235 citations · Full text

Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

Meletios Α. Dimopoulos, Antonio Palumbo, Paolo Corradini et al. · Blood · 2016 · 162 citations · Full text

Down-regulation of LFA-1 Adhesion Receptors by C- <i>myc</i> Oncogene in Human B Lymphoblastoid Cells

Giorgio Inghirami, F Grignani, Lars Sternås et al. · Science · 1990 · 135 citations